Allergan CEO Brent Saunders will head up commercial operations as president and COO after Pfizer’s merger deal with Allergan closes. At the same time, Pfizer’s vaccines and oncology drugs will combine with its global innovative products business, creating one big unit, and some Allergan businesses will hook up with consumer healthcare.

Albert Bourla will run the combined drugs and vaccines unit. The established products business will remain, with current exec John Young at the helm and all of Hospira’s commercial operations in his charge.